CRISPR Therapeutics (NASDAQ:CRSP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a research report report published on Saturday morning.

CRSP has been the subject of a number of other reports. Citizens Jmp reissued a “market outperform” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, July 6th. Citigroup upped their price target on CRISPR Therapeutics from $82.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Evercore reiterated an “outperform” rating and set a $76.00 price target on shares of CRISPR Therapeutics in a research note on Monday, May 11th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. Finally, UBS Group set a $80.00 price objective on CRISPR Therapeutics in a research note on Friday, June 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $68.06.

CRISPR Therapeutics Trading Down 0.0%

Shares of CRSP stock opened at $53.51 on Friday. The company has a 50 day moving average of $52.36 and a 200-day moving average of $52.31. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a 12-month low of $44.12 and a 12-month high of $78.48. The firm has a market cap of $5.17 billion, a P/E ratio of -11.24 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The company had revenue of $10.18 million during the quarter. Sell-side analysts anticipate that CRISPR Therapeutics will post -4.53 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG lifted its position in CRISPR Therapeutics by 7.7% during the fourth quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock valued at $132,366,000 after purchasing an additional 180,580 shares during the last quarter. Norges Bank bought a new position in shares of CRISPR Therapeutics in the 4th quarter worth $25,706,000. Leonteq Securities AG bought a new position in shares of CRISPR Therapeutics in the 4th quarter worth $1,155,000. Canal Insurance CO purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at $1,670,000. Finally, Wealth Enhancement Trust Services Inc. purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $2,032,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.